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Abstract 
 
Tissue engineering has emerged as a promising scientific field potentially 
yielding in vitro developed tissue to replace degenerative or injured 
tissues in vivo, thus avoiding the donor site morbidity associated with 
reconstructive surgery. Integral to the process is the role of scaffolds and 
the biomaterials used to form them. This review explores the concept of 
scaffold based tissue engineering and design considerations. The scaffold 
needs to have certain mechanical and architectural properties, it needs to 
be biocompatible and biodegradable, and allow combination with 
bioactive molecules.  We also discuss scaffolding techniques, different 
biomaterial options and fabrication technologies, and future areas of 
development. 
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1.Introduction 
Population growth coupled with increasing life expectancy has increased the burden 
of orthopaedic pathology. As medical technology progresses it faces the demand of 
developing viable solutions to the processes of trauma and degeneration with resultant 
damage to biological tissues causing pain and impaired function. Current strategies of 
treatment encompass autografts (transplant of patients own tissue to sites of injury), 
allografts (transplant of tissue from one patient to another) and joint replacement 
procedures. Autografting is associated with donor site morbidity and restricted by the 
fact there is a limit to how much tissue can be taken from a donor site without 
compromising its function. Allografting has the inherent difficulties associated with 
immune system rejection and the mismatch between the number of patients and 
donors, and joint replacement is expensive and limited by implant survival issues. 
 
Resultantly  ‘Tissue Engineering’ has emerged as a ‘multidisciplinary field that 
applies the principles of engineering and life sciences toward the development of 
biological substitutes that restore, maintain, or improve tissue function or a whole 
organ’ (1-3). The essence of this field is the in vitro expansion of specific cells on 
porous matrices (scaffolds) to create three dimensional (3D) tissues that can be 
implanted into the site of tissue injury (4-6). Huge scientific interest has been attracted 
and research in this discipline has been myriad over the last twenty years with the 
seemingly unlimited possibilities it offers.  
 
Integral to the process is the concept of the ‘tissue engineering triad’ composing of a) 
a scaffold which provides structure for tissue growth, b) a reservoir  of cells to enable 
the development of tissue and c) growth stimulating signals (or ‘bioreactors’) to direct 
the subsequent interaction between cells and scaffold (7-9). Scaffolds are critical to 
the process as cells cultured in vitro form two dimensional sheets incompatible with 
3D in vivo tissues, unless they are grown on 3D scaffolding. 
 
A biomaterial is any substance, other than drugs, synthetic or natural in origin, which 
can be used for any period of time, which augments or replaces any tissue organ or 
function of the body. Scaffolds are therefore the biomaterial basis of tissue 
engineering and represent an area of intense research to develop a successful 
application of tissue engineering which has so far been unrealised. This article will 
offer a review into the development and use of biomaterials as scaffolds in 
musculoskeletal tissue engineering. 
2. Demands of a Scaffold 
The structure of natural tissues serves as a guide to the design rationale within the 
field. A key concept is the role of extracellular matrix (ECM) which acts as an 
anchorage point for the majority of cells within the tissue – effectively forming a 
biological scaffold supporting cell proliferation and differentiation into mature tissue. 
The use of biomaterial scaffolds within tissue engineering is an attempt to mimic the 
ECM and facilitate cell mediated tissue regeneration (10, 11). Resultantly the 
characteristics of an effective scaffold parallel those of in vivo extra cellular matrix. 
These will vary depending on the tissue e.g. bone (12, 13), cartilage (14), meniscus 
(15), ligaments and tendons (16, 17). The limiting factor is the diversity of types of 
ECM within the body and their tissue specific composition (18-20) effectively 
curtailing the development of a single ‘best fit’ scaffold. Nevertheless it has been 
established that scaffold biomaterials should possess key characteristics as follows: 
 
2.1 Mechanical and Architectural Properties 
The scaffold must have sufficient mechanical strength to maintain the structure of the 
tissue into which it is implanted and the ability to resist the forces the tissue is 
routinely exposed to in vivo. This feature must be present from the time it is 
implanted until remodelling has taken place. Studies have shown that not only are 
mechanical properties imperative for implant survival the proliferating cells exhibit 
mechanosensitivity with scaffold stiffness influencing which cell lineages would 
preferentially differentiate on them in the case of stem cells (21) and which cell types 
adhere in the case of mature cells (22). The challenge in this regard is ensuring that 
the scaffold whilst being strong exhibits sufficient porosity in its structure to facilitate 
vascularisation, cellular penetration and efficient transport of oxygen, nutrients and 
waste products akin to the ECM.  Equilibrium between these two design 
considerations is vital to the success of the scaffold. 
 
2.2 Biocompatibility and Biodegradability  
Key to the process is the need for the biomaterials used as scaffold material to be 
immunologically compatible to avoid an excessive inflammatory response and 
subsequent rejection and also should have high affinity for cells to allow them to 
interact and adhere to the scaffold.  Scaffolds are not permanent implants and as such 
must be designed to be degradable allowing the body to replace the structure with its 
own tissue specific ECM. The rate of degradation should be similar to the rate at 
which new matrix is produced by the regenerating tissue to avoid mechanical collapse. 
Degradation occurs enzymatically or hydrolytically and can be influenced by scaffold 
design. It has been shown that scaffolds which are completely or partially degradable 
exhibit improved ECM distribution in comparison to non degradable scaffolds (23). 
 
2.3 Manufacturing Considerations  
The scaffold should be cost effective and there should be availability of batch 
production to make it viable in the clinical setting. Furthermore it should be possible 
to make it into varying shapes and sizes as demanded and consideration should be 
given to how it is packaged i.e. it should be amenable to sterilisation as per other 
surgical implants.  The endeavour to develop a material and structure which most 
closely displays these characteristics is what steers current research with the ultimate 
aim of developing a clinically useful tissue engineering derived treatment.  Scaffold 
design and development throughout the past decade can be considered both in terms 
of materials used and scaffolding technique, it is pertinent to consider both in 
reviewing the development of scaffolds. 
3. Scaffolding Technique 
Broadly speaking there have been four techniques employed throughout the period of 
research that are discussed in detail below. The advantages and disadvantages of each 
of these techniques are outlined in Table 1. 
 
3.1 Pre-Constructed Porous Scaffolds  
This represents the most established and widespread technique in which cells are 
‘seeded’ in laboratory constructed porous scaffolds. The materials used are far 
reaching and can be broadly classified into three categories namely natural, synthetic 
and composite / semi-synthetic (24) which will be reviewed later.  Examples of 
naturally existing biomaterials are organic polymers including polysaccharides, 
inorganic ceramics such as calcium phosphates and more total constructs such as 
allograft derived ECM. Unfortunately despite displaying excellent biocompatibility 
they lack the required mechanical strength necessary for use in musculoskeletal tissue 
engineering.  The composite biomaterials have subsequently been developed to 
address this short coming and are a combination of natural materials reinforced with 
synthetics (25) to improve mechanical strength.  Synthetic biomaterials can be organic 
materials such as synthetic polymers like polylactic acid (PLA) and inorganic 
materials for example bioglass. The perceived advantage of these over natural 
materials is that their structure can tailored to give a wide range of mechanical and 
architectural possibilities, however this is somewhat negated by their lack of 
bicompatability inhibiting cell adhesion and proliferation on their surfaces. Again the 
composite materials which attempt to combine the positive properties of both have 
been developed to overcome this for example coating synthetic materials in collagen 
(26). 
  
The technique has both strengths and weaknesses in comparison to others.  
As the scaffolds are constructed in vitro the mechanical and architectural properties 
can be manipulated to develop scaffolds displaying analogous characteristics of the 
tissue specific ECM it is being implanted into. The technique also affords the use of a 
diverse range of biomaterials and as such affords flexibility in developing an 
appropriately designed scaffold, tailored to the varying demands of the tissue into 
which it is implanted. The major weakness is the difficulty of seeding the cells onto 
the scaffold in vitro. Limitations in the process can lead to unevenly distributed cells 
throughout its structure with the resultant construct displaying heterogeneous 
properties. 
 
3.2 Cell Seeding of Allograft Derived ECM   
This technique involves removing cellular antigens from allograft (or xenograft) 
tissues whilst preserving the ECM to develop immunologically tolerated scaffolds to 
which cells are then seeded in vitro. The ECM is decellularised by a variety of 
techniques including freeze thaw cycles and EDTA treatment (27). The decellularised 
ECM can then be used to replace an equivalent tissue to its base structure (28) or to 
replace a tissue different from its native state (7, 29, 30). Advantages of this technique 
include its superb biocompatibility, the potential for preserved growth factors to 
stimulate cell proliferation on the scaffold and guide remodelling of the damaged 
tissue (31). The major disadvantage is that retained cellular components may 
stimulate an immune response and cell seeding difficulties and sequelae as for the 
previous technique. 
 
3.3 Cell Sheets 
This technique has been developed in Japan (32, 33) and involves the culture of cells 
on a temperature responsive polymer and inducing them to produce ECM and form 
into sheets. This can be repeated to produce multiple single layer sheets which can be 
bonded together to form thicker matrix. The structure of these matrices encourages 
neovascularisation much more readily than cell seeded scaffolds, however its value 
with regards musculoskeletal tissue engineering is limited as it would be very difficult 
to construct ECM rich tissues (due to the small volume of ECM produced by each 
sheet) which are typically found in bone and cartilage (12-14, 34). The technique is 
more applicable to tissues with high cell density such as corneal epithelium (35). 
 
3.4 Encapsulation of Cells in Hydrogel Matrix   
The principle of this technique is to ensnare living cells within a polymeric semi-
permeable membrane which allows diffusion of nutrients and oxygen in and waste 
products out, whilst also preventing immune recognition of the encapsulated cells (36). 
Typically hydrogels are used which are ‘cross linked polymeric networks which have 
the capacity to hold water within their porous structure’ (37). The driving force for its 
development has been transplant medicine with its applications including transplant of 
xenogenic pancreatic islet cells (38). The theoretical advantage of this technique is 
that the biomaterials used, from their base state as liquid monomers can be initiated to 
self construct solid 3D polymer meshes, with cells encapsulated (39).Enabling the 
complex to be delivered by injection as a liquid to the target tissue and initiated to set 
into the required shape. This potentially avoids open surgical procedures. So far its 
applicability for musculoskeletal tissue engineering has been limited by the poor 
mechanical properties of hydrogels. 
 
4. Biomaterial Options 
The biomaterial options which have been explored so far are broadly categorized into 
three groups namely, natural, synthetically derived or composite/ semi –synthetic (24). 
They have generally been modified for use in this domain from other established 
surgical uses including haemostatic agents, sutures and surgical site dressings (40). 
The review will focus on the established materials in these classes.  
 
4.1 Synthetic Materials 
The perceived advantage of this group is that they can be produced under controlled 
methods enabling bespoke design and producing predictable mechanical and physical 
properties. The most commonly used group is saturated aliphatic polyesters consisting 
of polylactic acid (PLA), polyglycolic acid (PGA), polylacticcoglycolide 
(PLGA)polycarprolactones (PCL). These polymers are degraded through hydrolytic 
de-esterification into monomers that are excreted via naturally occurring pathways 
and as such meet the demands of a biodegradable scaffold. There degradation rates 
and mechanical properties can be manipulated through the use of copolymers and 
adjusting molecular weight to satisfy the demand for specific structural characteristics 
for different applications. There is already emerging evidence of their successful 
application in tissue engineering as scaffolds for gene delivery (41) and more general 
applications (42). Polypropylene fumarate (PPF) is a linear polyester also with good 
biocompatibility and degradation parameters. It has the advantage over the other 
example polymers of potential use as an injectable material and has been explored as 
is initiated in situ to form a cross linked solid polymer. It has been explored for use in 
bone replacement tissue engineering (43) There are however limitations to these 
polymers with experimental data highlighting that they undergo bulk degradation 
which can lead to premature mechanical failure and the resultant degradation products 
can cause a strong inflammatory reaction further compromising their structure and 
ultimate success as a scaffold (44, 45). The combination of these polymers with 
ceramics such as hydroxyapatite is one strategy being explored to reduce the 
inflammatory response (46, 47). 
 
Ceramics represent a large group particularly used in bone tissue engineering. They 
have been used in orthopaedic implants for many years and have been shown to have 
excellent bone bonding properties allied with excellent biocompatibility (48). The 
mechanism for this bone bonding is postulated to be through the formation of a 
carbonated hydroxyapatite (HCA) layer on the surface of the ceramic which acts as a 
biological interface with host tissue (49). This property lends itself to tissue 
engineering applications to prevent scaffold loosening following implantation. 
Furthermore ceramics have been shown to encourage vascularization, foster cell 
adhesion, growth and differentiation to osteoblasts and support enzymatic activity 
favouring success as tissue engineering scaffolds. (50-52) Examples of specific 
ceramics used as scaffolds include β-tricalcium phosphates, hydroxyapatite, Bioglass 
and calcium sulphate (12, 13, 53-56). The limitations of these materials are that they 
lack the desired mechanical properties needed to facilitate their use as load bearing 
scaffolds due to low compressive strength and fracture toughness. 
4.2 Natural Materials 
These materials represent nature-designed biological options which typically 
overcome the issue of bioactivity posed by synthetic polymers. Cells readily adhere to 
and proliferate on their surface and they are typically readily biodegradable. 
Collagen represents the most widely explored natural biomaterial. It is the most 
copious protein in mammalian tissue and a key component of extracellular matrix 
found in bone, tendon and cartilage – key tissues in musculoskeletal medicine (12-17, 
57). It has been shown to readily allow cellular attachment and induce chemotaxis due 
to the topography of its surface  - a key challenge when using synthetic materials and 
has seen it widely used on its own or in combination with other materials in tissue 
engineering applications (58-60). It effectiveness has been limited by concerns 
regarding transmission of infective diseases, inflammatory reactions, poor mechanical 
properties and uncontrolled biodegradability (61), the combination of collagen with 
synthetic materials to form composites has characterized the response to these issues 
(60, 61). 
 
Polysaccharides are a further group of natural biomaterials, they have the ability to 
form hydrogels conferring the advantages described above.  A key sub group is 
proteogylycans which make up one of the major macromolecules in articular cartilage 
(14). Chitosan is an analog of this group and is derived from chitin which is found in 
arthropod skeletons. It has been shown to have bioactivity with chemoatrractive 
properties (62) and osteoconduction and is emerging as a biomaterial option (63). 
Further examples include starch (64), fibrin and decellularised extracellular matrix as 
described above (65). Despite their bioactive advantages the natural biomaterials pose 
challenges during fabrication resulting in heterogeneous structures and are difficult to 
mass produce consistently, furthermore they have proved to lack the required 
mechanical properties for load bearing musculoskeletal  tissue engineering 
applications. 
4.3 Composite / Semi Synthetic 
This is the current focus of scaffold engineering. It involves the amalgamation of 
differing materials into a composite structure in an attempt to overcome the 
characteristic deficiencies of the individual constituents – i.e. combining materials 
having good mechanical properties and biodegradability with those displaying 
bioactivity. The main areas of research are bio-ceramics (combination of synthetic 
polymers with ceramics), synthetic and natural polymers combined and collagen 
amalgamated with synthetic polymers. 
Examples include collagen/hydroxyapatite composites that has been demonstrated to 
induce bone formation and reabsorption similar to autologous bone transplant (59, 60, 
65). PLA (polyactide-aliginate amalgam) (66) which has supported the chondro-
induction of mesenchymal stem cells in vitro and collagen microsponges integrated 
into PGLA meshes (67). 
5. Fabrication Technologies 
This has formed a separate but equally important area of research to the choice of 
biomaterial. The overall goal is to create a mechanically strong and porous scaffold 
with a 3D structure to allow cell proliferation. The following options are the existing 
technologies, and their advantages and disadvantages are outlined in Table 1. 
 
Different Fabrication 
Technologies 
Advantages Disadvantages 
Solvent Casting and Technically easy Only creates thin sheets of 
Particulate Leaching material 
Solvents used can inhibit 
cell attachment and 
proliferation 
Textile Methods Technically easy 
Can be co-spun with other 
materials such as collagen 
Difficulties in controlling 
pore size and rigidity of 
the scaffold 
Phase Separation Better control over 
topography and the 
characteristics of the 
material  
Difficulty with cell 
survival necessitating 
composite scaffolds or 
combining it with other 
fabrication methods 
Solid Freeform Fabrication 
/ Rapid Prototyping 
Internal micro-structure of 
the scaffolds can be 
specifically controlled 
Cost  
Long time required to 
fabricate the scaffold 
Table 1: Advantages and Disadvantages of different fabrication methods 
 
5.1 Solvent Casting and Particulate Leaching  
As a technique this involves combining the polymer biomaterial (dissolved in a 
solvent) with soluble particles and casting the composite into a 3D mould. The 
particulates are subsequently leached away via chemical reaction to create pores in the 
scaffold. The size of the pores can be controlled by the size of particles used (68). 
This technique is technically easy requiring non-specilaised equipment, however the 
limitations are that it can only be used to create thin sheets of material and that the 
solvents used can inhibit cell attachment and proliferation (69, 70). 
 
5.2 Textile Methods  
Woven and non-woven fibres can be bonded together using heat or adhesives as in 
fibre bonding (71) or electrospinning (72) can be used, which generates electrostatic 
forces to overcome surface tension of polymers to create a fibre jet. Commonly PGA 
and PLA are used and can be co-spun with other materials such as collagen to 
combine the advantages of both. Again these are relatively simple techniques but are 
limited by difficulties in controlling pore size and rigidity of the scaffold. PGA 
scaffolds fabricated by these techniques have been used to engineer cartilage (14, 73) 
and tendon (16, 17, 74). 
 
5.3 Phase Separation  
This technique is based on changes in thermal energy to create separation of a 
homogenous polymer solution into a multi-phase system. With separation the solution 
separates into a polymer rich phase and a polymer lean phase. Subsequently solvent is 
extracted and this creates pores. As a result of the conditions created, the topography 
and the characteristics of the material can be controlled (75, 76). The process has been 
used to develop scaffolds in vitro for tissue engineering applications for bone and soft 
tissues (77, 78). Difficulties have been encountered with cell survival on scaffolds 
produced this way and this challenge has lead to the development of composite 
scaffolds using this technique and combining it with other fabrication methods in 
attempts to make them viable (79, 80). 
 
5.4 Solid Freeform Fabrication / Rapid Prototyping  
Computer data including computer aided design, CT and MRI data is used to create 
custom designs of 3D scaffolds using a variety of techniques such as 3D printing, 
selective laser sintering and stereolithography (81, 82). This technique is increasing in 
popularity as the internal micro-structure of the scaffolds can be specifically 
controlled – giving precise pore size, geometry and orientation allowing bespoke 
designs encouraging specific cell adhesion and propagation. The major limitations of 
the technique are the cost and the long time required to fabricate the scaffold 
compared to other techniques. 
6. Combination with Bioactive Molecules 
Both scaffold architecture and material can influence how scaffolds interact with cells 
an important consideration as explored above. An emerging further technique to 
improve bioactivity is to incorporate biologically active molecules into their structure 
(83, 84). The leading examples are through growth factor inclusion (85-88) and gene 
delivery (86) with the aim of influencing cell proliferation, differentiation, migration 
and gene expression to encourage tissue regeneration. 
7. Current Status and Future Areas of Development 
The review has summarised the current options available in terms of technique, 
biomaterial options and fabrication technologies. The plethora of existing options 
represents the myriad attempts to design a suitable bioactive scaffold that can be used 
clinically. The challenge is to balance the demands of required mechanical strength 
with architecture which has cell permissive internal structure and is sympathetic to the 
cellular response of the host tissue providing a suitable environment for tissue 
regeneration. So far the literature demonstrates very few examples of scaffolds that 
have been used clinically, spinal surgery has seen examples of scaffolds used in vivo 
with combination of recombinant human bone morphogenic protein-2 (rh BMP-2) 
with hydroxyapatite and tricalcium phosphate for spinal fusion with apparent success 
(87). Other examples exist on the market with limited data for example OSIGRAFT 
(Stryker) combining rhBMP-7 in a in a bovine collagen scaffold is indicated for 
delayed union of tibial fractures (88). Regarding systems designed for soft tissue 
structures treatment of rotator cuff tears has already seen scaffold based products 
implanted and tested.  The results demonstrate no improvement in healing compared 
to standard treatment approaches highlighting the difficulties still faced in developing 
successful tissue engineering treatments (89, 90). 
Research continues en-mass to develop the ideal material for scaffold applications 
with particular attention being paid to vascularisation strategies (91) bio-instructive 
and stimuli-responsive properties (92) and as delivery systems for growth factors and 
cytokines (92, 93) all factors which are increasingly being recognised as crucial to the 
survival, integration and ultimately success  of scaffold based tissue engineered 
implants. 
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